Advances in the treatment of metastatic colorectal cancer

Oncologist

Volumn 10, Issue SUPPL. 3, 2005, Pages 40-48

  Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Fluorouracil; Irinotecan; Metastatic; Oxaliplatin; Quality of life

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYANOCOBALAMIN; CYTOTOXIC AGENT; EDOTECARIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE B; EPOTHILONE DERIVATIVE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GEFITINIB; IRINOTECAN; IXABEPILONE; OXALIPLATIN; PEMETREXED; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ALOPECIA; ANAPHYLAXIS; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; INFUSION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 31444450593     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-90003-40     Document Type: Review

References (46)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
4. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-1743.
5. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
6. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-1197.
7. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
8. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
9. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
10. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
11. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
12. Ducreux M, Adenis A, Bennouna J et al. Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from an interim safety analysis. J Clin Oncol 2005;23:270s. (Updated based on presentation.)
13. Arkenau H, Schmoll H, Kubicka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis. J Clin Oncol 2005;23:247s. (Updated based on presentation.)
14. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:129a. (Updated based on presentation.)
15. Harba A, Peinert S, Grothe W et al. Weekly administration of 5-fluorouracil (5-FU), folinic acid (FA), oxaliplatin (L-OHP) and irinotecan (CPT-11) [FUFOXIRI] for patients with metastatic gastric or colorectal cancer. J Clin Oncol 2005;23:300s. (Updated based on presentation.)
16. Ferrari VD, Valcamonico F, Amoroso V et al. FAFOXIRI: a phase II trial of an alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer. J Clin Oncol 2005;23:285s. (Updated based on presentation.)
17. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091.
18. Sastre J, Massuti B, Tabernero JM et al. Preliminary results of a randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). J Clin Oncol 2005;23:252s. (Updated based on presentation.)
19. Jordan K, Kellner O, Kegel T et al. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 2004;4:46-50.
20. Park SH, Bang SM, Cho EK et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 2004;66:353-357.
21. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
22. Seymour MT. Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). J Clin Oncol 2005;23:250s. (Updated based on presentation.)
23. Kohne CH, Van Cutsem E, Wils JA et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003;22:254.
24. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
25. Kohne C, de Greve J, Bokemeyer C et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. J Clin Oncol 2005;23:252s. (Updated based on presentation.)
26. Schalhorn A, Ludwig F, Quietzsch D et al. Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): the FIRE-trial. J Clin Oncol 2005;23:250s. (Updated based on presentation.)
27. Fernando N, Yu D, Morse M et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 2005;23:260s. (Updated based on presentation.)
28. Hochster HS, Welles L, Hart L et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. J Clin Oncol 2005;23:249s. (Updated based on presentation.)
29. Mitchell E, Marshall J, Chang J et al. Randomized phase III study of 3 irinotecan regimens in 1st-line metastatic colorectal cancer (CRC): safety/tolerability of irinotecan + oral capecitabine with or without celecoxib (BICC). J Clin Oncol 2005;23:283s. (Updated based on presentation.)
30. Diaz Rubio ED, Tabernero J, van Cutsem E et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005;23:254s. (Updated based on presentation.)
31. Fisher GA, Kuo T, Cho CD et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 2004;22(post-meeting edition):356.
32. Zampino MG, Lorizzo K, Massacesi C et al. First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. J Clin Oncol 2005;23:285s. (Updated based on presentation.)
33. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
34. Keilholz U, Arnold D, Niederle N et al. Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. J Clin Oncol 2005;23:264s. (Updated based on presentation.)
35. Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005;23:251s. (Updated based on presentation.)
36. Sobrero A, Scheithauer W, Maurel J et al. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of the first 400 patients in a randomized phase III trial (EPIC). J Clin Oncol 2005;23:266s. (Updated based on presentation.)
37. Saltz LB, Lenz H, Hochster H et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 2005;23:248s. (Updated based on presentation.)
38. Cripps C, Burnell M, Jolivet J et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-1179.
39. John W, Picus J, Blanke CD et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000;88:1807-1813.
40. Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
41. Atkins JN, Jacobs S, Wieand S et al. Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the NSABP foundation research program. Proc Am Soc Clin Oncol 2003;22:276.
42. Nahum K, Shiba D, Padavanija P et al. Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecannaïve metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22:274.
43. Poplin E, Moore M, O'Dwyer P et al. Safety and efficacy of EPO906 in patients with advanced colorectal cancer: a review of 2 phase II trials. Proc Am Soc Clin Oncol 2003;22:283.
44. Eng C, Kindler HL, Skoog L et al. The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003;22:282.
45. Chawla A, Kabbinavar F, Holmgren E et al. Quality of life (QoL) impact of bevacizumab (BV) when combined with irinotecan + 5-FU/leucovor in (IFL) and 5-FU/leucovor in (FL) for metastatic colorectal cancer (mCRC). J Clin Oncol 2005;23:262s. (Updated based on presentation.)
46. Segalla J, van Eyll B, Federico M et al. Evaluation of quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC) treated with capecitabine (X). J Clin Oncol 2005;23:751s. (Updated based on presentation.)